1. Home
  2. HLI vs UTHR Comparison

HLI vs UTHR Comparison

Compare HLI & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HLI
  • UTHR
  • Stock Information
  • Founded
  • HLI 1972
  • UTHR 1996
  • Country
  • HLI United States
  • UTHR United States
  • Employees
  • HLI N/A
  • UTHR N/A
  • Industry
  • HLI Investment Managers
  • UTHR Biotechnology: Pharmaceutical Preparations
  • Sector
  • HLI Finance
  • UTHR Health Care
  • Exchange
  • HLI Nasdaq
  • UTHR Nasdaq
  • Market Cap
  • HLI 14.4B
  • UTHR 20.7B
  • IPO Year
  • HLI 2015
  • UTHR 1999
  • Fundamental
  • Price
  • HLI $178.18
  • UTHR $465.76
  • Analyst Decision
  • HLI Hold
  • UTHR Buy
  • Analyst Count
  • HLI 9
  • UTHR 12
  • Target Price
  • HLI $205.38
  • UTHR $495.08
  • AVG Volume (30 Days)
  • HLI 563.3K
  • UTHR 569.8K
  • Earning Date
  • HLI 10-30-2025
  • UTHR 10-29-2025
  • Dividend Yield
  • HLI 1.30%
  • UTHR N/A
  • EPS Growth
  • HLI 26.59
  • UTHR 16.08
  • EPS
  • HLI 6.19
  • UTHR 26.38
  • Revenue
  • HLI $2,565,361,000.00
  • UTHR $3,128,400,000.00
  • Revenue This Year
  • HLI $14.85
  • UTHR $13.68
  • Revenue Next Year
  • HLI $13.67
  • UTHR $5.63
  • P/E Ratio
  • HLI $29.83
  • UTHR $17.50
  • Revenue Growth
  • HLI 21.00
  • UTHR 13.50
  • 52 Week Low
  • HLI $137.99
  • UTHR $266.98
  • 52 Week High
  • HLI $211.78
  • UTHR $479.50
  • Technical
  • Relative Strength Index (RSI)
  • HLI 34.89
  • UTHR 65.97
  • Support Level
  • HLI $180.17
  • UTHR $444.04
  • Resistance Level
  • HLI $186.11
  • UTHR $464.27
  • Average True Range (ATR)
  • HLI 5.43
  • UTHR 15.76
  • MACD
  • HLI -0.59
  • UTHR 1.56
  • Stochastic Oscillator
  • HLI 8.17
  • UTHR 79.89

About HLI Houlihan Lokey Inc.

Houlihan Lokey Inc is an investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, valuation, and strategic consulting. The firm serves corporations, institutions, and governments world-wide with offices in the United States, Europe, and the Asia-Pacific region. The company operates in three segments. In the Corporate Finance business segment, it provides M&A and capital markets advisory services. Through the Financial Restructuring business segment, the company advises on some of the complex restructurings around the world. The Financial and Valuation Advisory Services business segment provides valuation and financial opinion, and financial and strategic consulting practices in the United States.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: